The advanced and unique proton micro-multileaf collimator technology is integrated into the MEVION S250i with HYPERSCAN, making pencil beam scanning sharper and faster and delivering robust intensity modulated proton therapy.
Mevion Medical Systems, a developer in compact proton therapy, is showcasing its pencil beam scanning HYPERSCAN with Adaptive Aperture at the 2016 ASTRO Annual Meeting in Boston, September 25 to 28. The advanced and unique proton micro-multileaf collimator (mMLC) technology is integrated into the MEVION S250i with HYPERSCAN, making pencil beam scanning sharper and faster and delivering robust intensity modulated proton therapy (IMPT).
HYPERSCAN with Adaptive Aperture delivers a pencil beam that is up to 50x faster and 3x sharper than conventional systems used for IMPT, and it can scan a typical lung tumor in less than two seconds.
The technology includes a low-profile mMLC system designed specifically for pencil beam scanning that is capable of delivering the sharpest penumbra physically achievable with protons without the need for manual apertures and adjustments. Its novel and unique layer-by-layer specific beam collimation and blocking achieves leading 1 to 3 mm collimated spot sizes, for all energies, at any depth.
“In the same way Mevion changed the industry when we invented compact proton therapy, we’re defining Adaptive IMPT with the breakthrough development of the adaptive aperture,” said Joseph K. Jachinowski, the president and CEO of Mevion Medical Systems. “HYPERSCAN with Adaptive Aperture completely eliminates the need for manual apertures and manual adjustments. This allows for sharper penumbra, faster volumetric scanning and robust clinical treatments to be safely delivered.”
“HYPERSCAN with Adaptive Aperture has been precisely engineered to deliver the sharpest penumbra achievable by protons, thus minimizing dose uncertainty at the target edges and unnecessary dose to surrounding healthy tissue,” said James Cooley, senior accelerator engineer at Mevion who led the development of the technology. “With a very low profile, the adaptive aperture is ideal for treating pediatric tumors or shallow brain tumors where small spot sizes have been difficult to achieve by conventional systems.”
Mevion Medical Systems
mevion.com
![An illustration showing the Edwards Lifesciences Sapien M3 transcatheter mitral valve replacement (TMVR) system's valve being placed in the heart. [Image courtesy of Edwards Lifesciences]](https://www.medicaldesignandoutsourcing.com/wp-content/uploads/2025/04/Edwards-Lifesciences-Sapien-M3-TMVR-valve-delivery-268x170.jpg)
